The United Kingdom's Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorisation for the first-in-human clinical trial to assess United States-based Sangamo Therapeutics' Chimeric Antigen Receptor Regulatory T Cell (CAR-Treq) therapy TX200, it was reported yesterday.
TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). It is an autologous (cells collected from the patient) HLA-A2-targeted CAR-Treg cell therapy. The company aims to open the first clinical sites for the STEADFAST study in 2020.
Adrian Woolfson, BM, BCh, PhD, head of Research and Development at Sangamo, said, 'Being the first company to test a CAR-Treg candidate in humans is an important milestone for Sangamo and this exciting new frontier of cellular therapy. We believe that the TX200 program will be invaluable in expanding our understanding of the safety and mechanism of action of CAR-Treg cells and their relevance in the clinic. This innovative and personalised cellular therapy approach for HLA-A2 mismatched kidney transplantation is designed to help regulate the body's immune system specifically and locally to promote acceptance of an immunologically mismatched donor organ. Beyond transplantation, we plan to explore the potential of CAR-Tregs in a range of autoimmune and inflammatory diseases.'
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007